Your last point is a good one ,i.e. having a deal in place is important. Small Biotech that fail to secure a deal before or on approval are especially risky to hold , because revenue is always slow to materialise ,and costs of launching a drug in competition with big pharma are too great. Achaogen was destroyed in short order in this situation, although they had the antibiotic pricing headwind to contend with as well.

Hopefully Vyera are capable of a good launch, but they will be up against large competitors .